Results 121 to 130 of about 33,038 (222)

The role of lysophosphatidic acid metabolism in castration-resistant prostate cancer progression. [PDF]

Front Oncol
Feng J, Liu J, He Y.
europepmc   +1 more source

[18F]PSMA‐1007 PET–Based Recurrence Site Distribution and Predictors of Metastatic Disease in Patients With Biochemical Recurrence of Prostate Cancer

International Journal of Urology, Volume 33, Issue 8, August 2026.
ABSTRACT Objectives Prostate‐specific membrane antigen positron emission tomography (PSMA‐PET) is a sensitive imaging modality for detecting recurrent prostate cancer following definitive local therapy. However, evidence on 18F‐labeled PSMA tracers in Japanese patients with biochemical recurrence (BCR) remains limited.
Koji Hatano, Tadashi Watabe, Takero Hirata, Masatoshi Konishi, Tomohiro Kanaki, Masaru Tani, Toshiki Oka, Yu Ishizuya, Takuji Hayashi, Yoshiyuki Yamamoto, Taigo Kato, Atsunari Kawashima, Kazutoshi Fujita, Motohide Uemura, Frederik L. Giesel, Norio Nonomura   +15 more
wiley   +1 more source

Myosteatosis Predicts Poor Prognosis in Patients With Castration-Resistant Prostate Cancer Treated With Enzalutamide. [PDF]

Int J Urol
Kanaki T, Hatano K, Oka T, Tani M, Konishi M, Liu Y, Horitani H, Matsukawa A, Inoguchi S, Yoshimura A, Horibe Y, Sassi N, Okuda Y, Ishizuya Y, Hayashi T, Yamamoto Y, Kato T, Kawashima A, Nonomura N.   +18 more
europepmc   +1 more source

Real‐World Outcomes of Radium‐223 Therapy in Metastatic Castration‐Resistant Prostate Cancer: Predictive Value of PSA Doubling Time and Enzalutamide Continuation

International Journal of Urology, Volume 33, Issue 8, August 2026.
ABSTRACT Background Radium‐223 dichloride (Ra‐223) is an effective treatment for metastatic castration‐resistant prostate cancer (mCRPC) with bone metastases. However, predictive factors associated with treatment efficacy remain unclear. This study evaluated prognostic factors associated with the efficacy of Ra‐223 and investigated outcomes according ...
Kodai Abe, Yoshiyuki Miyazawa, Shun Nakazawa, Mai Onose, Yuta Maeno, Yusuke Tsuji, Azusa Kanayama, Akira Ohtsu, Yuji Fujizuka, Seiji Arai, Masashi Nomura, Yoshitaka Sekine, Hidekazu Koike, Hiroshi Matsui, Kazuhiro Suzuki   +14 more
wiley   +1 more source

Undifferentiated Castration-Resistant Prostate Cancer Successfully Treated With Carboplatin and Paclitaxel. [PDF]

Case Rep Urol
Sano M, Shimbo M, Ohgita S, Kanomata N, Hattori K, Endo F.   +5 more
europepmc   +1 more source

Patient-reported outcomes in castration-resistant prostate cancer with bone metastases treated with radium-223 with or without olaparib. [PDF]

Cancer
McKay RR, Xie W, Ajmera A, Araneta A, Folefac E, Hussain A, Kyriakopoulos CE, Olson A, Parikh M, Parikh R, Saraiya B, Shapiro GI.   +11 more
europepmc   +1 more source

Erratum: [Corrigendum] Inhibition of Rac1 reverses enzalutamide resistance in castration-resistant prostate cancer. [PDF]

Oncol Lett
Chen X, Yin L, Qiao G, Li Y, Li B, Bai Y, Feng F.   +6 more
europepmc   +1 more source

Androgen receptor reactivation in castration-resistant prostate cancer: mechanisms, epigenetic adaptation, and therapeutic vulnerabilities. [PDF]

Front Oncol
Guo J, Wu K, Ma Z, Guo S, Wang F, Lu L.
europepmc   +1 more source

PARP Inhibition in Castration-Resistant Prostate Cancer [PDF]

Future Oncology, 2016
Lucia, Nappi, Martin E, Gleave
openaire   +2 more sources

Phase Separation of NFIB Suppresses SLC3A2-Mediated Ferroptosis in Castration-Resistant Prostate Cancer. [PDF]

Adv Sci (Weinh)
Li Q, Chen D, Xia Y, Long Y, Huang N, Li R, Shi M, Kadier M, Luo H, Chen X, Liu H, Jiang G.   +11 more
europepmc   +1 more source